keyword
https://read.qxmd.com/read/38630911/uterine-inflammatory-myofibroblastic-tumors-p16-as-a-surrogate-for-cdkn2a-deletion-and-predictor-of-aggressive-behavior
#1
JOURNAL ARTICLE
Kyle M Devins, Zehra Ordulu, Rachelle P Mendoza, Sabrina Croce, Rishikesh Haridas, Pankhuri Wanjari, Andre Pinto, Esther Oliva, Jennifer A Bennett
Uterine inflammatory myofibroblastic tumors (IMTs) are rare mesenchymal neoplasms of uncertain malignant potential. Aside from the recently described risk stratification score, which has not been validated by other studies, and rare reports of aberrant p16 expression in malignant tumors, there are no criteria to reliably predict behavior. Herein, we evaluated the clinicopathologic features and p16 expression patterns in 30 IMTs, with genomic profiling performed in a subset (13 malignant, 3 benign). Fifteen patients had malignant IMTs, defined by extrauterine disease at diagnosis (n=5) or recurrence (n=10; median: 24 mo)...
April 17, 2024: American Journal of Surgical Pathology
https://read.qxmd.com/read/38630551/efficacy-of-pembrolizumab-and-biomarker-analysis-in-patients-with-wgs-based-intermediate-to-high-tumor-mutational-load-results-from-the-drug-rediscovery-protocol
#2
JOURNAL ARTICLE
Birgit S Geurts, Laurien J Zeverijn, Lindsay V M Leek, Jade M van Berge Henegouwen, Louisa R Hoes, Hanneke van der Wijngaart, Vincent van der Noort, Joris van de Haar, Annemiek van Ommen-Nijhof, Marleen Kok, Paul Roepman, Anne M L Jansen, Wendy W J de Leng, Maja J A de Jonge, Ann Hoeben, Carla M L van Herpen, Hans M Westgeest, Lodewyk F A Wessels, Henk M W Verheul, Hans Gelderblom, Emile E Voest
PURPOSE: To evaluate efficacy of pembrolizumab across multiple cancer types harboring different levels of Whole-Genome Sequencing (WGS)-based tumor mutational load (TML; total of non-synonymous mutations across the genome) in patients included in the Drug Rediscovery Protocol (NCT02925234). PATIENTS AND METHODS: Patients with solid, treatment-refractory, microsatellite-stable tumors were enrolled in cohort A: breast cancer TML 140-290, cohort B: tumor-agnostic cohort TML 140-290, and cohort C: tumor-agnostic cohort TML >290...
April 17, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38630548/monitoring-hepatocellular-carcinoma-using-tumor-content-in-circulating-cell-free-dna
#3
JOURNAL ARTICLE
Shifeng Lian, Chenyu Lu, Fugui Li, Xia Yu, Limei Ai, Biao-Hua Wu, Xueyi Gong, Wenjing Zhou, Xuejun Liang, Jiyun Zhan, Yong Yuan, Fang Fang, Zhiwei Liu, Mingfang Ji, Zongli Zheng
PURPOSE: To evaluate the utility of tumor content in circulating cell-free DNA (ccfDNA) for monitoring hepatocellular carcinoma (HCC) throughout its natural history. METHODS: We included 67 hepatitis B virus (HBV)-related HCC patients, of whom 17 had paired pre- and post-treatment samples, and 90 controls. Additionally, in a prospective cohort with HBV surface antigen-positive participants recruited in 2012 and followed up biannually with blood sample collections until 2019, we included 270 repeated samples before diagnosis from 63 participants who later developed HCC (pre-HCC samples)...
April 17, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38630384/rebound-growth-of-braf-mutant-pediatric-glioma-cells-after-mapki-withdrawal-is-associated-with-mapk-reactivation-and-secretion-of-microglia-recruiting-cytokines
#4
JOURNAL ARTICLE
Daniela Kocher, Lei Cao, Romain Guiho, Melanie Langhammer, Yun-Lu Lai, Pauline Becker, Hiba Hamdi, Dennis Friedel, Florian Selt, David Vonhören, Julia Zaman, Gintvile Valinciute, Sonja Herter, Daniel Picard, Johanna Rettenmeier, Kendra K Maass, Kristian W Pajtler, Marc Remke, Andreas von Deimling, Stefan Pusch, Stefan M Pfister, Ina Oehme, David T W Jones, Sebastian Halbach, Tilman Brummer, Juan Pedro Martinez-Barbera, Olaf Witt, Till Milde, Romain Sigaud
INTRODUCTION: Patients with pediatric low-grade gliomas (pLGGs), the most common primary brain tumors in children, can often benefit from MAPK inhibitor (MAPKi) treatment. However, rapid tumor regrowth, also referred to as rebound growth, may occur once treatment is stopped, constituting a significant clinical challenge. METHODS: Four patient-derived pediatric glioma models were investigated to model rebound growth in vitro based on viable cell counts in response to MAPKi treatment and withdrawal...
April 17, 2024: Journal of Neuro-oncology
https://read.qxmd.com/read/38629100/cadmium-induced-annulus-fibrosus-cell-senescence-contributes-to-intervertebral-disc-degeneration-via-the-jnk-p53-signaling-pathway
#5
JOURNAL ARTICLE
Xin Liu, Wenjie Zhao, Man Hu, Yu Zhang, Jingcheng Wang, Liang Zhang
OBJECTIVES: Investigating the impact of cadmium (Cd) on annulus fibrosus (AF) cells and its potential mechanism was the purpose of the current study. MATERIALS AND METHODS: Cd was cultivated in different concentrations (0, 1, 5, 10, and 20 μM) on AF cells and the potential effects of the metal were assessed. Using the CCK-8 method, cell viability and proliferation were identified. Using transcriptome analysis, the annulus fibrosus cells were sequenced both with and without cadmium chloride...
2024: Iranian Journal of Basic Medical Sciences
https://read.qxmd.com/read/38629072/neoadjuvant-chemotherapy-is-associated-with-suppression-of-the-b-cell-centered-immune-landscape-in-pancreatic-ductal-adenocarcinoma
#6
JOURNAL ARTICLE
Luise Rupp, Ina Dietsche, Maximilian Kießler, Ulrich Sommer, Alexander Muckenhuber, Katja Steiger, Casper W F van Eijck, Leonard Richter, Rouzanna Istvanffy, Carsten Jäger, Helmut Friess, Casper H J van Eijck, Ihsan Ekin Demir, Carmen Mota Reyes, Marc Schmitz
Pancreatic ductal adenocarcinoma (PDAC) is typically diagnosed at advanced stages and associated with early distant metastasis and poor survival. Besides clinical factors, the tumor microenvironment (TME) emerged as a crucial determinant of patient survival and therapy response in many tumors, including PDAC. Thus, the presence of tumor-infiltrating lymphocytes and the formation of tertiary lymphoid structures (TLS) is associated with longer survival in PDAC. Although neoadjuvant therapy (NeoTx) has improved the management of locally advanced tumors, detailed insight into its effect on various TME components is limited...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38628712/identification-of-n7-methylguanosine-related-mirnas-as-potential-biomarkers-for-prognosis-and-drug-response-in-breast-cancer
#7
JOURNAL ARTICLE
Danian Dai, Hongkai Zhuang, Mao Shu, Lezi Chen, Chen Long, Hongmei Wu, Bo Chen
OBJECTIVES: The impact of N7-methylguanosine (m7G) on tumor progression and the regulatory role of microRNAs (miRNAs) in immune function significantly influence breast cancer (BC) prognosis. Investigating the interplay between m7G modification and miRNAs provides novel insights for assessing prognostics and drug responses in BC. MATERIALS AND METHODS: RNA sequences (miRNA and mRNA profiles) and clinical data for BC were acquired from the Cancer Genome Atlas (TCGA) database...
April 30, 2024: Heliyon
https://read.qxmd.com/read/38628708/disulfidptosis-related-lncrna-signature-reveals-immune-microenvironment-and-novel-molecular-subtyping-of-stomach-adenocarcinoma
#8
JOURNAL ARTICLE
Jinze Li, Chuqi Xia, Yilin Song, Lu Zhang, Wei Shang, Ning Xu, Qiyu Lu, Daoming Liang
The main challenge in treating stomach adenocarcinoma (STAD) is chemotherapy resistance, which is characterized by changes in the immune microenvironment. Disulfidptosis, a novel form of programmed cell death, is involved in STAD but its mechanism is not fully understood. Long non-coding RNAs (LncRNAs) may play a role in regulating disulfidptosis and influencing the immune microenvironment and chemotherapy resistance in STAD. This study aims to establish disulfidptosis-related lncRNA (DRL) features and explore their significance in the immune microenvironment and chemotherapy resistance in STAD patients...
April 30, 2024: Heliyon
https://read.qxmd.com/read/38628662/prevalence-and-associations-of-co-occurrence-of-nfe2l2-mutations-and-chromosome-3q26-amplification-in-lung-cancer
#9
JOURNAL ARTICLE
Jinfeng Liu, Sijie Liu, Dan Li, Hongbin Li, Fan Zhang
Background   NFE2L2 (nuclear factor erythroid-2-related factor-2) encodes a basic leucine zipper (bZIP) transcription factor and exhibits variations in various tumor types, including lung cancer. In this study, we comprehensively investigated the impact of simultaneous mutations on the survival of NFE2L2 -mutant lung cancer patients within specific subgroups. Methods  A cohort of 1,103 lung cancer patients was analyzed using hybridization capture-based next-generation sequencing. Results  The NFE2L2 gene had alterations in 3...
June 2024: Global medical genetics
https://read.qxmd.com/read/38628557/impressive-and-prolonged-response-with-lenvatinib-in-a-highly-pretreated-patient-with-metastatic-clear-cell-renal-cancer-a-case-report
#10
Sara Demurtas, Mara Frascaroli, Federico Sottotetti, Alessandro Rametta, Giuseppe Procopio, Laura Deborah Locati
Clear cell renal carcinoma (ccRCC) can occur in young people and could be associated with an aggressive behavior. While for the first-line treatment in metastatic disease, there is an agreement to rely on an immunotherapy (IO)-based combination regimen, no standard second-line regimens exist. Generally, tyrosine kinase inhibitors (TKIs) are employed, even in sequence, although no trials have demonstrated yet the best succession. Herein, we present the case of a 39-year-old male, with a very aggressive ccRCC with somatic VHL mutation and distant metastases at diagnosis...
2024: Journal of Kidney Cancer and VHL
https://read.qxmd.com/read/38628547/a-lipid-plga-nanocomplex-to-reshape-tumor-immune-microenvironment-for-colon-cancer-therapy
#11
JOURNAL ARTICLE
Nan Zhang, Qiqi Sun, Junhua Li, Jing Li, Lei Tang, Quan Zhao, Yuji Pu, Gaofeng Liang, Bin He, Wenxia Gao, Jianlin Chen
Immune checkpoint blockade therapy provides a new strategy for tumor treatment; however, the insufficient infiltration of cytotoxic T cells and immunosuppression in tumor microenvironment lead to unsatisfied effects. Herein, we reported a lipid/PLGA nanocomplex (RDCM) co-loaded with the photosensitizer Ce6 and the indoleamine 2,3-dioxygenase (IDO) inhibitor 1MT to improve immunotherapy of colon cancer. Arginine-glycine-aspartic acid (RGD) as the targeting moiety was conjugated on 1,2-distearoyl-snglycero-3-phosphoethanolamine lipid via polyethylene glycol (PEG), and programmed cell death-ligand 1 (PD-L1) peptide inhibitor DPPA (sequence: CPLGVRGK-GGG-d(NYSKPTDRQYHF)) was immobilized on the terminal group of PEG via matrix metalloproteinase 2 sensitive peptide linker...
2024: Regenerative Biomaterials
https://read.qxmd.com/read/38628239/study-on-mngs-technique-in-diagnosing-pneumocystis-jirovecii-pneumonia-in-non-hiv-infected-patients
#12
JOURNAL ARTICLE
Shuai Li, Xue Han, Jing Ma, Guo-Hong Huang, Shu-Ting Yang, Chang-Min Wang
OBJECTIVE: To investigate the value of metagenomic Next-Generation Sequencing (mNGS) in diagnosing Pneumocystis jirovecii pneumonia (PJP) in non-human immunodeficiency virus (HIV)-infected patients. METHODS: In this retrospective study, non-HIV-infected patients with PJP and those diagnosed with non-PJP from August 2022 to December 2024 were selected as subjects. The presence of Pneumocystis jirovecii (PJ) and other co-pathogens in bronchoalveolar lavage fluid (BALF) was analyzed, and the diagnostic efficacy of NGS, polymerase chain reaction (PCR) and serum 1,3-β-D-glucan (BDG) in PJP was compared with the reference standard of clinical compound diagnosis...
2024: Infection and Drug Resistance
https://read.qxmd.com/read/38627939/attention-guided-variational-graph-autoencoders-reveal-heterogeneity-in-spatial-transcriptomics
#13
JOURNAL ARTICLE
Lixin Lei, Kaitai Han, Zijun Wang, Chaojing Shi, Zhenghui Wang, Ruoyan Dai, Zhiwei Zhang, Mengqiu Wang, Qianjin Guo
The latest breakthroughs in spatially resolved transcriptomics technology offer comprehensive opportunities to delve into gene expression patterns within the tissue microenvironment. However, the precise identification of spatial domains within tissues remains challenging. In this study, we introduce AttentionVGAE (AVGN), which integrates slice images, spatial information and raw gene expression while calibrating low-quality gene expression. By combining the variational graph autoencoder with multi-head attention blocks (MHA blocks), AVGN captures spatial relationships in tissue gene expression, adaptively focusing on key features and alleviating the need for prior knowledge of cluster numbers, thereby achieving superior clustering performance...
March 27, 2024: Briefings in Bioinformatics
https://read.qxmd.com/read/38627854/integration-of-single-cell-rna-seq-and-bulk-rna-seq-data-to-construct-and-validate-a-cancer-associated-fibroblast-related-prognostic-signature-for-patients-with-ovarian-cancer
#14
JOURNAL ARTICLE
Liang Shen, Aihua Li, Jing Cui, Haixia Liu, Shiqian Zhang
BACKGROUND: To establish a prognostic risk profile for ovarian cancer (OC) patients based on cancer-associated fibroblasts (CAFs) and gain a comprehensive understanding of their role in OC progression, prognosis, and therapeutic efficacy. METHODS: Data on OC single-cell RNA sequencing (scRNA-seq) and total RNA-seq were collected from the GEO and TCGA databases. Seurat R program was used to analyze scRNA-seq data and identify CAFs clusters corresponding to CAFs markers...
April 16, 2024: Journal of Ovarian Research
https://read.qxmd.com/read/38627727/an-exosome-mrna-related-gene-risk-model-to-evaluate-the-tumor-microenvironment-and-predict-prognosis-in-hepatocellular-carcinoma
#15
JOURNAL ARTICLE
Zhonghai Du, Xiuchen Han, Liping Zhu, Li Li, Leandro Castellano, Justin Stebbing, Ling Peng, Zhiqiang Wang
BACKGROUND: The interplay between exosomes and the tumor microenvironment (TME) remains unclear. We investigated the influence of exosomes on the TME in hepatocellular carcinoma (HCC), focusing on their mRNA expression profile. METHODS: mRNA expression profiles of exosomes were obtained from exoRBase. RNA sequencing data from HCC patients' tumors were acquired from The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC). An exosome mRNA-related risk score model of prognostic value was established...
April 16, 2024: BMC Medical Genomics
https://read.qxmd.com/read/38627602/braf-v600e-mutant-metastatic-nsclc-disease-overview-and-treatment-landscape
#16
REVIEW
David Planchard, Rachel E Sanborn, Marcelo V Negrao, Aria Vaishnavi, Egbert F Smit
In this review, we cover the current understanding of BRAF mutations and associated clinical characteristics in patients with metastatic NSCLC, approved and emerging treatment options, BRAF sequencing approaches, and unmet needs. The BRAFV600E mutation confers constitutive activity of the MAPK pathway, leading to enhanced growth, proliferation, and survival of tumor cells. Testing for BRAF mutations enables patients to be treated with therapies that directly target BRAFV600E and the MAPK pathway, but BRAF testing lags behind other oncogene testing in metastatic NSCLC...
April 16, 2024: NPJ Precision Oncology
https://read.qxmd.com/read/38627278/identification-and-validation-of-a-lactate-metabolism-related-six-gene-prognostic-signature-in-intrahepatic-cholangiocarcinoma
#17
JOURNAL ARTICLE
Chen Sang, Li Yan, Jian Lin, Youpei Lin, Qiang Gao, Xia Shen
PURPOSE: Intrahepatic cholangiocarcinoma (iCCA) is a highly malignant and fatal liver tumor with increasing incidence worldwide. Lactate metabolism has been recently reported as a crucial contributor to tumor progression and immune regulation in the tumor microenvironment. However, it remains poorly identified about the biological functions of lactate metabolism in iCCA, which hinders the development of prognostic tools and therapeutic interventions. METHODS: The univariate Cox regression analysis and Boruta algorithm were utilized to identify key lactate metabolism-related genes (LMRGs), and a prognostic signature was constructed based on LMRG scores...
April 16, 2024: Journal of Cancer Research and Clinical Oncology
https://read.qxmd.com/read/38627035/engot-en20-gog-3083-xport-ec-042-a-phase-iii-randomized-placebo-controlled-double-blind-multicenter-trial-of-selinexor-in-maintenance-therapy-after-systemic-therapy-for-patients-with-p53-wild-type-advanced-or-recurrent-endometrial-carcinoma-rationale-methods
#18
JOURNAL ARTICLE
Ignace Vergote, Alejandro Perez Fidalgo, Giorgio Valabrega, Bradley J Monk, Thomas Herzog, David Cibula, Nicoletta Colombo, Bhavana Pothuri, Jalid Sehouli, Jacob Korach, Joyce Barlin, Christos A Papadimitriou, Toon van Gorp, Debra Richardson, Michael McCarthy, Yoland Antill, Mansoor Raza Mirza, Kai Li, Pratheek Kalyanapu, Brian Slomovitz, Robert L Coleman
BACKGROUND: Patients with advanced/recurrent endometrial cancer have a poor prognosis and limited treatment options. Biomarkers such as tumor protein 53 ( TP53 ) in endometrial cancer can integrate novel strategies for improved and individualized treatment that could impact patient outcomes. In an exploratory analysis of the phase III ENGOT-EN5/GOG-3055/SIENDO study of selinexor maintenance monotherapy 80 mg in advanced/recurrent endometrial cancer, a pre-specified subgroup of patients with TP53 wild type (wt) endometrial cancer showed preliminary activity at long-term follow-up with a generally manageable safety profile (median progression-free survival 27...
April 16, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38626741/diagnostic-conundrum-of-a-sertoli-cell-tumor-in-a-2-year-old-girl-with-peripheral-precocious-puberty-and-a-caf%C3%A3-au-lait-macule-a-case-report
#19
Lauren A Ray, Deborah F Billmire, Michael J Ferguson, Erica A Eugster
INTRODUCTION: Ovarian Sertoli cell tumors represent a subset of sex cord-stromal tumors and are exceedingly rare in prepubertal children. Here we report a girl with vaginal bleeding due to a Sertoli cell tumor who was originally thought to have McCune-Albright syndrome (MAS). CASE PRESENTATION: A previously healthy girl presented at age two years six months with breast development and vaginal bleeding. On exam, she had Tanner 4 breasts, Tanner 1 pubic hair, estrogenized vaginal mucosa, and a café-au-lait macule...
April 16, 2024: Hormone Research in Pædiatrics
https://read.qxmd.com/read/38626292/bcl2a1-neoepitopes-elicited-cytotoxic-t-lymphocytes-are-a-promising-individualized-immunotherapy-of-pancreatic-cancer
#20
JOURNAL ARTICLE
Shengzhe Lin, Jingwen Hong, Suxin Wu, Chenlu Zhu, Fang Liu, Wansong Lin, Xinran Cai, Yunbin Ye, Yanling Chen
Conventional treatments have shown a limited efficacy for pancreatic cancer, and immunotherapy is an emerging option for treatment of this highly fatal malignancy. Neoantigen is critical to improving the efficacy of tumor-specific immunotherapy. The cancer and peripheral blood specimens from human leukocyte antigen (HLA)-A0201 positive pancreatic cancer patient were subjected to next-generation sequencing and bioinformatics analyses were performed to screen high-affinity and highly stable neoepitopes. The activation of cytotoxic T lymphocytes (CTLs) by the mutBCL2A111-20 neoepitope targeting B-cell lymphoma 2-related protein A1 (BCL2A1) mutant epitope was investigated, and the cytotoxicity of mutBCL2A111-20 neoepitope-specific CTLs to pancreatic cancer cells was evaluated...
April 16, 2024: Journal of Leukocyte Biology
keyword
keyword
108479
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.